BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 9月 2024 07:00:46 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 9月 2024 10:02:32 条件 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 8月 2024 10:17:26 条件 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

28 8月 2024 09:45:07 条件 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

26 8月 2024 09:45:03 条件 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

23 8月 2024 10:45:41 条件 NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

22 8月 2024 07:00:00 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 8月 2024 09:45:50 条件 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 8月 2024 09:45:08 条件 NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 8月 2024 07:00:24 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8月 2024 07:00:47 条件 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 7月 2024 09:56:40 条件 NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 7月 2024 07:00:09 条件 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 7月 2024 07:00:00 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 7月 2024 07:00:06 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 6月 2024 07:00:59 条件 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 6月 2024 04:00:13 条件 Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 5月 2024 07:00:53 条件 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 5月 2024 07:00:00 条件 Nasdaq GlobeNewswire